Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review.

Abstract

BACKGROUND:

In unresectable dermatofibrosarcoma protuberans (DFSP), no clear guideline exists regarding the use of tyrosine kinase inhibitors (TKI) versus radiotherapy. This study reviews current literature regarding TKI and radiotherapy in unresectable DFSP.

METHODS:

Following PROSPERO registration (CRD42021232508), a systematic literature search was performed including all studies reporting clinical results of TKI and/or radiotherapy in the treatment of unresectable DFSP. A narrative synthesis was used to compare patient characteristics, outcomes, and adverse effects.

RESULTS:

Of 1345 screened studies, 14 were included for review. Patient age ranged 18-77 years and 55% were male. Radiotherapy patients exhibited lower grade disease than TKI patients. Overall clinical benefit following TKI ranged from 70% to 96%. Radiotherapy patients exhibited control or resolution on last follow-up in 90% of cases. Radiotherapy adverse effects were mild, while TKI adverse effects were more severe and managed with dose reduction.

CONCLUSION:

TKI may be employed in unresectable DFSP of all histology types whereas radiation alone may be limited to low-grade and classic-type DFSP. TKI may cause more severe adverse effects compared to radiation alone.

• Authors: Owen S Henry, Rebecca Platoff, Katherine S Cerniglia, Sai Batchu, Brandon J Goodwin, Georgianna Sandilos, Amanda Adams, Young K Hong
• Journal: American journal of surgery (Am J Surg) Vol. 225 Issue 2 Pg. 268-274 (02 2023) ISSN: 1879-1883 [Electronic] United States
• PMID: 36184329 (Publication Type: Journal Article, Review, Systematic Review)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Imatinib Mesylate
• Tyrosine Protein Kinase Inhibitors

Topics

• Humans
• Male
• Adolescent
• Young Adult
• Adult
• Middle Aged
• Aged
• Female
• Imatinib Mesylate (therapeutic use)
• Dermatofibrosarcoma (drug therapy, radiotherapy)
• Tyrosine Protein Kinase Inhibitors
• Skin Neoplasms (drug therapy, radiotherapy)